OVUROL OVULES

Indications

• Intestinal amoebiasis
• Urogenital trichomoniasis
• Giardiasis

Dosage

Children: For children aged 1 month to 11 years, the dosage is 50–75 mg/kg once, with a maximum of 2 g per dose. For children aged 12 to 17 years, the dosage is 2 g for a single dose, which may be repeated once if necessary.

Adults: The usual adult dosage is 2 g taken orally as a single dose for urogenital trichomoniasis or giardiasis, and 1.5 g to 2 g once daily for 3 to 6 days for intestinal amoebiasis.

Mechanism of action

Tinidazole acts as a prodrug and antiprotozoal agent. Its nitro group is reduced in Trichomonas by a ferredoxin-mediated electron transport system, generating free nitro radicals that covalently bind to DNA, causing DNA damage and cell death. The exact mechanism of action against Giardia and Entamoeba species is not fully understood but is believed to be similar to that of Trichomonas.

Pharmacodynamics

Tinidazole demonstrates in vitro and clinical activity against Trichomonas vaginalis, Giardia duodenalis (also known as G. lamblia), and Entamoeba histolytica. It does not exhibit significant activity against most strains of vaginal lactobacilli, which are beneficial bacteria in the vaginal flora.

Pharmacokinetics

Tinidazole is well absorbed following oral administration, with peak plasma concentrations occurring within 0.5 to 3 hours. It is extensively distributed throughout body tissues and fluids. The drug undergoes hepatic metabolism and is eliminated primarily through the urine, with a half-life of approximately 12 to 14 hours. Clinical and laboratory monitoring is advised if treatment extends beyond 10 days.

Adverse effects

• Abdominal pain
• Decreased appetite
• Diarrhoea
• Headache
• Nausea
• Skin reactions
• Vertigo
• Vomiting

Precautions

• Clinical and laboratory monitoring is advised if treatment exceeds 10 days

Pregnancy

Manufacturer advises avoiding use in the first trimester.

Breast-feeding

Present in milk; the manufacturer advises avoiding breastfeeding during and for 3 days after stopping treatment.

Storage

Store below 25°C, protect from moisture.

Formulations

• Tinidazole 500 mg tablets
• Tinidazole oral suspension

Indications

• Multiple myeloma
• Erythema nodosum leprosum
• HIV-related conditions
• Certain inflammatory conditions

Dosage

Children: Refer to specific prescribing guidelines as doses can vary based on condition and patient response.

Adults: Refer to specific prescribing guidelines as doses can vary based on condition and patient response.

Mechanism of action

Thalidomide exerts its effects by modulating the immune system. It inhibits the production of pro-inflammatory cytokines, such as TNF-alpha, and enhances the production of anti-inflammatory cytokines. Additionally, it interferes with the angiogenic process, which is the formation of new blood vessels, by inhibiting the activity of vascular endothelial growth factor (VEGF).

Pharmacodynamics

Thalidomide has immunomodulatory effects, leading to altered immune responses. Its anti-inflammatory action helps reduce symptoms associated with inflammatory conditions. The drug is known to induce cell cycle arrest and apoptosis in certain cancer cells, particularly in multiple myeloma, thus contributing to its antitumor effects.

Pharmacokinetics

Thalidomide is well-absorbed after oral administration, with peak plasma concentrations occurring within 2 to 6 hours. It has a long half-life, ranging from 5 to 7 hours in healthy individuals, and is extensively metabolized in the liver. The drug is eliminated primarily through the urine, with both parent compound and metabolites being excreted. Due to its lipophilicity, it can cross the blood-brain barrier.

Pregnancy

The use of caise during pregnancy should be approached with caution. It is important to consider potential risks versus benefits and consult healthcare professionals.

Breast-feeding

Caution is advised when using caise during breastfeeding. It is essential to evaluate the risks and benefits, and to consult healthcare providers for guidance.

Storage

Store caise in a cool, dry place, away from light and moisture. Ensure it is kept out of reach of children.

Indications

• Local anesthesia for surgical procedures
• Regional anesthesia (e.g., epidural, nerve block)
• Ventricular arrhythmias, including ventricular tachycardia
• Acute treatment of lifethreatening ventricular arrhythmias

Dosage

Children: Refer to specific guidelines or clinical protocols for paediatric dosing as it varies based on application and condition.

Adults: Refer to specific guidelines or clinical protocols for adult dosing as it varies based on application and condition.

Mechanism of action

Lidocaine exerts its effects by blocking voltage-gated sodium channels in neuronal cell membranes. This blockade inhibits the influx of sodium ions during depolarization, effectively preventing the generation and propagation of action potentials, leading to localized anesthesia. In the heart, lidocaine decreases automaticity and conduction velocity, which helps in controlling arrhythmias.

Pharmacodynamics

Lidocaine's onset of action is typically rapid, with local anesthetic effects occurring within minutes of administration. The duration of action is dose-dependent and varies according to the route of administration. It is generally effective for procedures requiring short to moderate anesthesia. As an antiarrhythmic, it is effective in treating ventricular tachycardia and preventing ventricular fibrillation.

Pharmacokinetics

Lidocaine is well absorbed following parenteral administration, with a bioavailability of approximately 90% when given intravenously. It is extensively metabolized in the liver via cytochrome P450 enzymes, particularly CYP1A2 and CYP3A4. The elimination half-life ranges from 1.5 to 2 hours. Lidocaine is primarily excreted in urine as metabolites, with less than 10% excreted unchanged.

Pregnancy

Lidocaine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is classified as a category B drug.

Breast-feeding

Lidocaine is excreted in breast milk in small amounts. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Indications

• Superficial fungal infections
• Tinea corporis
• Tinea pedis
• Tinea cruris
• Candidiasis

Dosage

Children: Refer to specific guidelines for dosage based on the child's age, weight, and condition being treated.

Adults: Refer to specific guidelines for dosage as it can vary based on formulation and condition being treated.

Mechanism of action

Ticonazole exerts its antifungal effects by inhibiting the enzyme lanosterol 14-alpha-demethylase, which is crucial in the biosynthesis of ergosterol. This inhibition leads to a depletion of ergosterol in the fungal cell membrane, causing increased membrane permeability and ultimately cell death.

Pharmacodynamics

The pharmacodynamics of ticonazole involve its ability to penetrate fungal cells and bind to specific enzymes in the ergosterol biosynthesis pathway. The resulting disruption of membrane integrity renders the fungi unable to maintain their cellular functions, leading to their death. Ticonazole demonstrates fungicidal activity against a variety of fungal pathogens, particularly those responsible for superficial infections.

Pharmacokinetics

Ticonazole is absorbed through the skin when applied topically and is distributed in the tissues. The systemic absorption is minimal with topical formulations. The drug is metabolized in the liver and is eliminated primarily through the urine. The half-life of ticonazole is variable based on the formulation and route of administration but is generally characterized by a short to moderate duration of action.

Contra-indications

• Hypersensitivity to ticonazole or any of its components
• Severe liver impairment

Adverse effects

• Local irritation
• Burning sensation
• Erythema
• Itching
• Allergic reactions

Interactions

• May interact with other antifungal agents
• Potential for increased local irritation if used with other topical medications

Precautions

• Use with caution in patients with a history of allergies
• Avoid contact with eyes
• Not recommended for systemic use

Pregnancy

Ticonazole should be used during pregnancy only if clearly needed and after assessing the risk-benefit ratio.

Breast-feeding

Caution is advised; the effects on nursing infants are unknown.

Storage

Store at room temperature, away from moisture and heat.

Formulations

• Topical cream
• Vaginal cream

Mechanism of action

Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is reduced in <i>Trichomonas</i> by a ferredoxin-mediated electron transport system. The free nitro radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind to DNA, causing DNA damage and leading to cell death. The mechanism by which tinidazole exhibits activity against <i>Giardia</i> and <i>Entamoeba</i> species is not known, though it is probably similar. The nitro group of tinidazole is reduced by cell extracts of Trichomonas. As a result of this reduction a free nitro radical is generated which may be responsible for the antiprotozoal activity. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.

Pharmacodynamics

Tinidazole is a synthetic antiprotozoal agent. Tinidazole demonstrates activity both in vitro and in clinical infections against the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>. Tinidazole does not appear to have activity against most strains of vaginal lactobacilli.